Clinical Pilot Study to Evaluate a Non-Invasive, Neurostimulation Device for Treatment of Migraine Headache
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Migraine Headache
- Sponsor
- Scion NeuroStim
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- Number of migraine headache days
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a single-site, prospective, non-randomized and open label study to investigate the feasibility of home-use CVS for the prevention of episodic migraine headache and specifically to better understand what type of waveform to apply.
Detailed Description
This study is a single-center, unblinded, non-randomized clinical trial for adjunctive prophylactic treatment of episodic migraine headache using neuromodulation device developed by Scion NeuroStim, LLC (SNS). The investigational use of the device for episodic migraine headache has been reviewed by the FDA and is classified as NSR (non-significant risk).
Investigators
Eligibility Criteria
Inclusion Criteria
- •A history of at least four, and not more than fourteen total monthly headache days of which between four and nine were migraine headache days. (Note: Patients were permitted continued access to migraine abortive medications and were being treated at the Duke University headache clinic.)
- •A history of some responsiveness (incomplete) to at least one and a maximum of two prophylactic pharmaceutical therapies (utilized concurrently);
- •The investigator must have confidence in the patient's ability to reliably complete and return the Daily Headache Diary.
- •Subject must be at least 18 years of age.
Exclusion Criteria
- •Individuals who were pregnant, who had a history of cardiovascular disease, who worked night shifts or who had vestibular migraine, menstrual migraine, post-traumatic migraine, a history of unstable mood disorder or unstable anxiety, moderate or greater hearing loss or a history of traumatic brain injury.
- •A history within the last six months of tobacco use, narcotic or barbiturates use or experiencing one or more analgesic rebound headaches.
Outcomes
Primary Outcomes
Number of migraine headache days
Time Frame: Length of the study, about 71 days
Daily Headache Diary will be used by subject. A headache day is defined as a twenty-four hour period which the subject has a headache.
Severity of each and of all headaches
Time Frame: Length of study, 71 days
Daily Headache Diary will be used by subject. Subject will assign the level of pain based on an eleven-point pain measurement scale from zero (no pain) to ten (most intense pain).
Secondary Outcomes
- Total Monthly Headache Pain Score(Length of study, about 71 days)